Intra-annular self-expanding valves had similar 1-year rates of death, disabling stroke, or heart failure hospitalization compared to supra-annular valves (HR 1.01; 95% CI 0.77-1.33; P=0.916).
Cohort (n=2,607)
Yes
Does an intra-annular self-expanding valve compared to a supra-annular self-expanding valve reduce the composite of all-cause death, disabling stroke, or heart failure hospitalisation in patients undergoing transfemoral TAVI?
Contemporary intra-annular and supra-annular self-expanding valves offer similar 1-year clinical and haemodynamic outcomes, though intra-annular valves have higher pacemaker rates and supra-annular valves have higher bleeding rates.
Effect estimate: HR 1.01 (95% CI 0.77-1.33)
Absolute Event Rate: 12.6% vs 11.3%
p-value: p=0.916
BACKGROUND: Contemporary self-expanding transcatheter heart valves (THVs) differ in leaflet position and frame architecture. Comparative data between new-generation intra-annular (IA) and supra-annular (SA) platforms remain limited. AIMS: We sought to compare 30-day and 1-year clinical and haemodynamic outcomes between contemporary intra-annular and supra-annular self-expanding THVs in a large multicentre real-world cohort. METHODS: Consecutive patients undergoing transfemoral transcatheter aortic valve implantation with a Navitor/Navitor Vision (IA self-expanding valve SEV) or Evolut FX/FX+ (SA-SEV) between June 2021 and April 2025 were included. The primary endpoint was the composite of all-cause death, disabling stroke, or heart failure hospitalisation at 1 year. Propensity score matching (PSM) was performed to adjust for baseline differences. RESULTS: Among 2,607 patients (IA-SEV: 1,604; SA-SEV: 1,003), PSM yielded 892 well-balanced pairs. Valve Academic Research Consortium 3 device success was achieved in 91.1% of IA-SEV patients and 90.9% of SA-SEV patients (p=0.868). Permanent pacemaker implantation was more frequent with IA-SEVs (22.1% vs 16.3%; p=0.007), whereas major or life-threatening bleeding was more common with SA-SEVs (4.2% vs 2.6%; p<0.001). At 1 year, the primary endpoint occurred in 12.6% of IA-SEV patients and 11.3% of SA-SEV patients (p=0.422) with no difference between groups in the time-to-event analysis (hazard ratio HR 1.01, 95% confidence interval CI: 0.77-1.33; p=0.916). The mean transvalvular gradients and rates of moderate or severe paravalvular leak remained low and similar between the two groups at 1 year. Findings were consistent in the unmatched cohort (HR 1.02, 95% CI: 0.81-1.31; p=0.835). CONCLUSIONS: In this large real-world registry, contemporary IA-SEVs and SA-SEVs demonstrated overall similar clinical outcomes and sustained haemodynamic performance at 1-year follow-up, despite differences in procedure-related endpoints between the groups.
Casenghi et al. (Wed,) conducted a cohort in Patients undergoing transfemoral transcatheter aortic valve implantation (n=2,607). Intra-annular self-expanding valves (Navitor/Navitor Vision) vs. Supra-annular self-expanding valves (Evolut FX/FX+) was evaluated on composite of all-cause death, disabling stroke, or heart failure hospitalisation at 1 year (HR 1.01, 95% CI 0.77-1.33, p=0.916). Intra-annular self-expanding valves had similar 1-year rates of death, disabling stroke, or heart failure hospitalization compared to supra-annular valves (HR 1.01; 95% CI 0.77-1.33; P=0.916).